膀胱内交替吉西他滨与BCG chemoimmunotherapy 治疗BCG暴露高危NMIBC的I期临床试验
PURPOSE: Retreatment with Bacillus Calmette-Guérin (BCG) alone is recommended for patients with BCG-exposed non-muscle-invasive bladder cancer (NMIBC), yet ∼50% recur and become "BCG-unresponsive." Strategies to improve the efficacy of BCG retreatment are urgently needed.…
要点
- GemBCG交替方案在高危BCG暴露NMIBC中安全耐受,无≥3级治疗相关不良事件。
- 6个月完全临床缓解率达96%(95%CI 80%-100%),早期疗效积极。
- 尿液T细胞趋化因子CXCL9/10/11升高、IL-6降低,提示肿瘤微环境免疫调节。
核心结论
- GemBCG安全、耐受良好,并显示有希望的早期疗效及肿瘤微环境调节作用。
研究设计与样本
- I期剂量递增试验(NCT04179162),纳入25例BCG暴露高危NMIBC患者,中位年龄68岁(IQR 64-75)。
- 双周膀胱内吉西他滨于第1、4、7、10周给药(共8剂,经改良持续再评估法从500 mg递增至2000 mg),每周膀胱内BCG(50 mg TICE)于第2、3、5、6、8、9周给药(共6剂)。
- 主要目标为确定最大耐受剂量,不良事件按CTCAE v5.0评估,关键次要结局为6个月完全临床缓解。
主要发现
- 25例中17例(68%)为原位癌±乳头状病变。
- 无治疗相关≥3级不良事件或剂量限制性毒性;72%报告1级不良事件,20%报告2级不良事件。
- 尿液中T细胞招募趋化因子CXCL9、CXCL10和CXCL11升高,免疫抑制性细胞因子IL-6降低。
临床怎么用
- 基于该I期数据,正在开展随机III期试验(Alliance A032303/NCT07000084)比较GemBCG与单用BCG再治疗BCG暴露高危NMIBC。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Retreatment with Bacillus Calmette-Guérin (BCG) alone is recommended for patients with BCG-exposed non-muscle-invasive bladder cancer (NMIBC), yet ∼50% recur and become "BCG-unresponsive." Strategies to improve the efficacy of BCG retreatment are urgently needed. MATERIALS AND METHODS: In this phase I dose-escalation trial of intravesical chemoimmunotherapy with gemcitabine and BCG (GemBCG) in patients with BCG-exposed high-grade NMIBC (NCT04179162), biweekly intravesical gemcitabine was given weeks 1, 4, 7, and 10 (8 doses total escalated from 500 to 2000 mg via a modified continual reassessment method) and weekly intravesical BCG (50 mg TICE) during weeks 2, 3, 5, 6, 8, and 9 (6 doses total). The primary objective was to define the maximally tolerated dose. Adverse events were assessed using CTCAE v5.0. The key secondary outcome was complete clinical response at 6 months. Analyses of tumor, urine, and blood samples were exploratory. RESULTS: Twenty-five patients enrolled (median age 68 [IQR 64-75] years) of whom 17 (68%) had carcinoma in situ ± papillary disease. No treatment-related grade ≥ 3 AEs or dose-limiting toxicities occurred; 72% reported grade 1 and 20% reported grade 2 AEs. Twenty-four of 25 patients (96%; 95% CI 80%-100%) achieved a complete clinical response at 6 months. T-cell recruitment chemokines (CXCL9, CXCL10, and CXCL11) increased, and the immunosuppressive cytokine IL-6 decreased in the urine with treatment. CONCLUSIONS: GemBCG was safe, well-tolerated, and demonstrated promising early efficacy and modification of the tumor microenvironment. Based on these data, a randomized phase III trial is testing GemBCG vs retreatment with BCG alone for BCG exposed high-grade NMIBC (Alliance A032303/NCT07000084).
引用
- Gaffney CD, Alam SM, Wald G, et al. A Phase I Clinical Trial of Chemoimmunotherapy With Alternating Intravesical Gemcitabine and Bacillus Calmette-Guérin (GemBCG) for BCG-Exposed High-Grade Non-Muscle-Invasive Bladder Cancer. J Urol. 2026. PMID: 42821609. doi:10.1097/JU.0000000000005324
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。